Active Biotech’s nomination committee proposes election of an additional new board member

As previously announced, Active Biotech's nomination committee has proposed that
the annual general meeting on 5 May 2011 re-elect Mats Arnhög, Klas Kärre,
Magnhild Sandberg-Wollheim and Peter Sjöstrand as board members and that Peter
Hofvenstam and Peter Thelin be elected new members of the board.

The nomination committee now expands its proposal and proposes that Mef Nilbert
be elected new member of the board. Mef Nilbert, M.D., PhD, is 44 years old,
chief physician at the oncology clinic at Skåne University Hospital and
professor of oncology at Lund University. Mef Nilbert also holds a cancer
research professorship at Copenhagen University. She has extensive experience
within the field of cancer research. According to the nomination committee, Mef
Nilbert would contribute further valuable expertise within cancer research.

For further information, please refer to the nomination committee's revised
proposal to the annual general meeting, which is available at Active Biotech's

Lund, April 14, 2011
Active Biotech AB (publ)

Active  Biotech AB  (NASDAQ OMX  NORDIC: ACTI)  is a  biotechnology company with
focus  on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase
are   laquinimod,   an   orally   administered   small   molecule   with  unique
immunomodulatory  properties for the  treatment of multiple  sclerosis, TASQ for
prostate  cancer and  ANYARA for  use in  cancer targeted  therapy, primarily of
renal  cell  cancer.  In  addition,  laquinimod  is  in Phase II development for
Crohn's  and Lupus.  Further projects  in clinical  development comprise the two
orally  administered compounds, 57- 57 for SLE and Systemic Sclerosis as well as
RhuDex(TM) for RA. Please visit  for more information.

Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00

Active Biotech is required under the Swedish Securities Market Act to make the
information in this press release public. The information was submitted for
publication at 1.30 p.m. CET on April 14, 2011.

Active Biotech’s nomination committee proposes election:

This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
    other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
     originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE